Drugs / Rutoside
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT06298383 | Jun 2025 → Feb 2026 | pulpitis | Cairo University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05681312 Comparator | May → Sep 2024 | — | University of Baghdad | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rutoside | “Tibrolin is a fixed dose combination of(Trypsin 48 mg, Bromelain 90 mg) and a bioflavonoid (Rutoside 100 mg)” NCT05681312 ↗ |
| Modality | Other / unclassified | “a bioflavonoid (Rutoside 100 mg)” NCT05681312 ↗ |